You are here

CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

Last updated on March 11, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Sutton, Surrey, SM2 5PT United Kingdom
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Advanced Non-Hematologic Malignancies
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Age greater than 18 years

- Documented advanced-stage non-hematologic malignancy for whom docetaxel monotherapy is
a reasonable treatment option

- Eastern Cooperative Oncology Group [ECOG] performance status 0-1

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Significant active cardiac disease

- Chemotherapy, biological or investigational agents within 4 weeks prior to dosing

- Inadequate bone marrow, renal, cardiac or liver function

NCT01653158
Pfizer
Completed
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Advanced Non-Hematologic Malignancies
NCT00915278
All Genders
18+
Years
Multiple Sites
Advanced Non-Hematologic Malignancies
NCT01653158
All Genders
18+
Years
Sutton, Surrey

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now